| 证券代码 | ODT.O |
| 证券名称 | Odonate Therapeutics Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2017-12-07 |
| 首发价格(元) | 24 USD |
| 首发数量(股) | 6250000 |
| 首发募资额(元) | 150,000,000.00 USD |
| 首发主承销商 | Goldman Sachs & Co. LLC,Jefferies LLC |
| 货币单位 | USD |
| 公司名称 | Odonate Therapeutics, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 4747 Executive Drive, Suite 510, San Diego, California, USA |
| 成立日期 | 2013-03 |
| 董事会主席 | Kevin C. Tang |
| 公司属地 | United States 美国 |
| 公司网址 | www.odonate.com |
| 电话 | +1 (858) 731-8180 |
| 传真 | - |
| 公司简介 | Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent belonging to a class of drugs known as taxanes, which are widely used in the treatment of cancer. In December 2017, Odonate initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives. |